Evidence map›Paper›PMID 39828865›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

An

Hiroyuki Suzuki, Saki Yamashita, Shoko Tanaka, Kento Kannaka, Ichiro Sasaki, Yasuhiro Ohshima, Shigeki Watanabe, Kazuhiro Ooe, Tadashi Watabe, Noriko S Ishioka and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Monte Carlo microdosimetry ofEJNMMI physics · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Unveiled Impact ofACS physical chemistry Au · 2026
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hiroyuki SuzukiGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan. h.suzuki@chiba-u.jp.ORCID 0000-0002-9560-4274
Saki YamashitaGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan.
Shoko TanakaGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan.
Kento KannakaGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan.ORCID 0000-0002-5919-1820
Ichiro SasakiDepartment of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Watanuki, Takasaki, 1233, 370-1292, Gunma, Japan.
Yasuhiro OhshimaDepartment of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Watanuki, Takasaki, 1233, 370-1292, Gunma, Japan.
Shigeki WatanabeDepartment of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Watanuki, Takasaki, 1233, 370-1292, Gunma, Japan.ORCID 0000-0002-8556-8580
Kazuhiro OoeRadioisotope Research Center, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.ORCID 0000-0002-8560-027X
Tadashi WatabeRadioisotope Research Center, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.ORCID 0000-0001-8658-2395
Noriko S IshiokaDepartment of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Watanuki, Takasaki, 1233, 370-1292, Gunma, Japan.
Hiroshi TanakaFaculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu, 279-0013, Chiba, Japan.ORCID 0000-0002-3661-9310
Tomoya UeharaGraduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan.ORCID 0000-0002-1140-9800

Funding

Japan Society for the Promotion of Science 16H06278Japan Society for the Promotion of Science 22K07686Japan Society for the Promotion of Science 23KK0291
6 · The paper itself

Abstract

purposePatients who develop metastatic melanoma have a very poor prognosis, and new treatments are needed to improve the response rates. Melanocortin-1 receptor (MC1R) is a promising target for radionuclide therapy of metastatic melanoma, and alpha-melanocyte stimulating hormone (α-MSH) peptide analogs show high affinities to MC1Rs. Because targeted alpha therapy (TAT) can be a desirable treatment for metastatic melanoma, this study aimed to develop an

methodsWe designed an α-MSH analog labeled with

resultsThe D-Glu-D-Arg linker was identified as the optimal hydrophilic linker because of its high affinity for MC1R and good biodistribution profile, especially with low accumulation in the liver and intestine. [

conclusion[

Indexed as

alpha-MSHAstatineMelanomaMolecular Targeted TherapyAnimalsCell Line, TumorHumansIsotope LabelingMelanoma, ExperimentalMiceNeoplasm MetastasisRadiopharmaceuticalsTissue Distributionalpha-MSHAstatineAstatine-211Radiopharmaceuticals211AtAlpha-melanocyte stimulating hormoneMelanocortin-1 receptorMetastatic melanomaTargeted alpha therapy

Identifiers

PMID39828865
PMCPMC12014842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.